Medtronic to spin off its diabetes business into a standalone, publicly traded company within 18 months, aiming to streamline its portfolio and focus on high-margin growth sectors.
Medtronic to spin off its diabetes business into a standalone, publicly traded company within 18 months, aiming to streamline its portfolio and focus on high-margin growth sectors.